·PIB·15 marks·250–350 words

Commercialisation of public-funded biomedical research can either widen access or privatise gains. Examine with reference to ICMR's technology transfer initiatives.

New · District CollectorCan you hold the district for 72 hours?Floods, a heatwave, an outbreak, a grievance queue. Take the decisions, see the consequences.Play →
In this answer
  1. How commercialisation widens access
  2. How it can privatise gains
  3. Way forward

Commercialisation means licensing inventions made with public money to firms that can manufacture, certify and distribute them. ICMR launched the Medical Innovations Patent Mitra in March 2025 [2], and it crossed 100 technology transfer deals in less than two years [1]. Whether it widens access or privatises gains depends on the licence terms, not on how many deals are signed.

How commercialisation widens access

  • Lab to market: A lab cannot mass-produce kits, but licensing brings in industry scale. Before the US Bayh-Dole Act (1980), very few government-owned patents were ever licensed [6].
  • Indigenous capacity: At the 3rd DHR-ICMR Summit, 20 agreements covering 8 technologies were signed with 9 Indian companies [1]. Nine technologies, including diagnostics and vaccines, were licensed at India MedTech Expo 2025 [3]. This supports Atmanirbhar Bharat in MedTech.
  • Open route: An Open Real-Time PCR kit for TB was released alongside Patent Mitra [2]. This shows ICMR can also release some technologies as open public goods.

How it can privatise gains

  • Taxpayers pay twice: The public funds the research and then pays the private price. An exclusive licence gives one firm control over pricing. The summit release does not say which type each licence is, so its "wider public use" aim [1] cannot be checked.
  • Deals ≠ products: Nine technologies produced 17 deals [3]. There is no public data on market launch, price or how many patients are reached.
  • Weak revenue case: NRDC's licensing income was under Rs 10 crore over three years [4]. DHR's 2026-27 budget is Rs 4,821 crore [5]. WIPO notes that many technology transfer offices run at a loss [6].
  • Mission drift: Pressure to license can pull scientists away from basic research [6]. This matters more because 16% of ICMR's scientist posts were vacant in 2023 [5].

Way forward

  • Public licence register: For every deal, publish the licence type, royalty, launch status and price.
  • Non-exclusive by default for fully public-funded diagnostics. Exclusive licences only for devices that need heavy investment, with the reason recorded.
  • Compulsory licensing under the Patents Act, 1970 as a safeguard.
  • Fill vacancies and move health research towards 5% of the Ministry's spending, as the Parliamentary Standing Committee recommended [5].

ICMR's deals show that public science can reach the market. The real question is not whether to license but on what terms. Transparent licensing that puts access first would align Patent Mitra with Article 47 and SDG 3, so that public research gives public returns.

Sources

  1. 13rd DHR-ICMR Health Research Excellence Summit, PIB release (Nov 2026)100 deals; 20 agreements, 8 technologies, 9 companies; "wider public use" aim; licence type not disclosed
  2. 2MoHFW: Union Health Minister inaugurates ISHTA 2025Patent Mitra launch (March 2025); Open Real-Time PCR kit for TB
  3. 3All India Radio News: ICMR licenses nine medical technologies at India MedTech Expo 2025nine technologies, 17 deals
  4. 4PIB: Parliament Question – Commercialisation and Transfer of Government-Developed TechnologiesNRDC licensing and royalty income
  5. 5PRS Legislative Research: Demand for Grants 2026-27 Analysis – Health and Family WelfareDHR budget; ICMR scientist vacancies; Standing Committee's 5% recommendation
  6. 6WIPO, World Intellectual Property Report 2011, Ch. 4: Harnessing Public Research for InnovationBayh-Dole; losses at transfer offices; risk to basic research

More from this note